Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature

Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature

<p><strong>Background</strong> There have been no studies of the patterns of post-marketing withdrawals of medicinal products to which adverse reactions have been attributed. We identified medicinal products that were withdrawn because of adverse drug reactions, examined the eviden...

书目详细资料
Main Authors:	Onakpoya, IJ, Heneghan, CJ, Aronson, JK
格式:	Journal article
语言:	English
出版:	BioMed Central 2016

相似书籍

Correction to: Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature
由: Igho J. Onakpoya, et al.
出版: (2019-03-01)

Post-marketing withdrawal of anti-obesity medicinal products because of adverse drug reactions: a systematic review.
由: Onakpoya, I, et al.
出版: (2016)

Post-marketing withdrawal of analgesic medications because of adverse drug reactions: a systematic review
由: Onakpoya, I, et al.
出版: (2017)

Worldwide withdrawal of medicinal products because of adverse drug reactions: a systematic review and analysis
由: Onakpoya, I, et al.
出版: (2016)

Postmarketing withdrawal of human medicinal products because of adverse reactions in animals: a systematic review and analysis.
由: Onakpoya, I, et al.
出版: (2017)

An evidence-based approach to the post-marketing withdrawal of medicinal products because of adverse reactions
由: Onakpoya, I
出版: (2017)

Post-marketing regulation of medicines withdrawn from the market because of drug-attributed deaths: An analysis of justification.
由: Onakpoya, I, et al.
出版: (2017)

Naltrexone‐bupropion (Mysimba®) in management of obesity: A systematic review and meta‐analysis of unpublished clinical study reports
由: Onakpoya, IJ, et al.
出版: (2020)

Signals of adverse drug reactions communicated by pharmacovigilance stakeholders: protocol for a scoping review of the global literature
由: Daniele Sartori, et al.
出版: (2020-08-01)

Withdrawal of cerivastatin from the world market
由: Pitt Bertram, et al.
出版: (2001-09-01)

Benefits and harms in pivotal trials of oral centrally acting antiobesity medicines: A systematic review and meta-analysis.
由: Onakpoya, I, et al.
出版: (2018)

Post-marketing drug withdrawals: pharmacovigilance success, regulatory problems : Arrêts de commercialisation de médicaments post-autorisation : succès de la pharmacovigilance, problèmes réglementaires
由: Aronson, J
出版: (2017)

Publishing histories of adverse reactions to medicaments anecdotally: the PHARMA guidelines for reporting suspected adverse drug reactions.
由: Aronson, J
出版: (2008)

Transmission of SARS-CoV-2 from pre and asymptomatic infected individuals: a systematic review update
由: Jefferson, T, et al.
出版: (2022)

An agenda for research on adverse drug reactions.
由: Aronson, J
出版: (2007)

Adverse drug reactions--no farewell to harms.
由: Aronson, J
出版: (2007)

Pharmacogenetics and adverse drug reactions
由: Ferner, R, et al.
出版: (2010)

REG 462 - Rekabentuk Konkrit
由: PPPB, Pusat Pengajian Perumahan Dan Bangunan
出版: (1995)

Withdrawn medicines included in the essential medicines lists of 136 countries.
由: Onella Charles, et al.
出版: (2019-01-01)

Recommendations of high-quality clinical practice guidelines related to the process of starting dialysis: a systematic review
由: Salas-Gama, K, et al.
出版: (2022)

20.462J / 3.962J Molecular Principles of Biomaterials (BE.462J), Spring 2003
由: Irvine, Darrell J.
出版: (2003)

The effectiveness and safety of Japanese traditional medicine (Kampo) in the treatment of climacteric symptoms
由: Onakpoya, I, et al.
出版: (2013)

Adverse drug reactions: definitions, diagnosis, and management.
由: Edwards, I, et al.
出版: (2000)

What evidence affects clinical practice? An analysis of Evidence-Based Medicine commentaries
由: Coombs, C, et al.
出版: (2017)

Spontaneous reporting to regulatory authorities of suspected adverse drug reactions to COVID-19 vaccines over time: the effect of publicity
由: Ferner, RE, et al.
出版: (2022)

Adverse drug reactions: keeping up to date.
由: Aronson, J, et al.
出版: (2002)

Is It Because I Can or Because of Who I Am?
由: María Laura Gonzalez-Canosa, et al.
出版: (2021-12-01)

Paradoxical reactions: Under-recognized adverse effects of drugs?
由: Hauben, M, et al.
出版: (2006)

National differences in publishing papers on adverse drug reactions.
由: Ferner, R, et al.
出版: (2005)

RMK462 - PENTADBIRAN TANAH FEBRUARI 1998
由: PPPB, Pusat Pengajian Perumahan Dan Bangunan
出版: (1998)

REG 462 - REKABENTUK KONKRIT JUN 1992
由: PPPB, Pusat Pengajian Perumahan Dan Bangunan
出版: (1992)

PGT 462: Pengelolaan Dan Penyelidikan Sekolah
由: PPIP, Pusat Pengajian Ilmu Pendidikan
出版: (1997)

PGT 462 Pengelolaan dan Penyeliaan Sekolah
由: PPIP, Pusat Pengajian Ilmu Pendidikan
出版: (1997)

Adverse Drug Reactions: History, Terminology, Classification, Causality, Frequency, Preventability
由: Aronson, J
出版: (2012)

Psychotropic drug-induced adverse drug reactions in 462,661 psychiatric inpatients in relation to age: results from a German drug surveillance program from 1993–2016
由: Johanna Seifert, et al.
出版: (2024-11-01)

The withdrawal of drugs from the market as a result of post-authorisation pharmacovigilance
由: Łukasz Dobrek
出版: (2022-08-01)

Stephens' Detection and Evaluation of Adverse Drug Reactions: Principles and Practice
由: Talbot, J, et al.
出版: (2012)

Stephens' Detection and Evaluation of Adverse Drug Reactions: Principles and Practice
由: Talbot, J, et al.
出版: (2012)

SARS-CoV-2 and the role of orofecal transmission: a systematic review
由: Heneghan, CJ, et al.
出版: (2021)

SARS-CoV-2 and the role of fomite transmission: a systematic review
由: Onakpoya, IJ, et al.
出版: (2021)